Advertisement
Organisation › Details
Regeneron (Group)
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world. *
Start | 1988-01-01 established | |
End | 1998-07-27 existent | |
Today | Regeneron Pharmaceuticals Inc. (Nasdaq: REGN) | |
Industry | biopharmaceutical | |
Street | Old Saw Mill River Rd. | |
City | 10591 Tarrytown, NY | |
Tel | +1-919-345-7400 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Regeneron Pharmaceuticals, Inc.. (4/19/22). "Press Release: Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types". Tarrytown, NY & Cambridge, MA. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Regeneron (Group)
- [1] Sanofi S.A.. (5/29/20). "Press Release: Sanofi Announces Closing of Regeneron Stock Sale". Paris....
- [2] Sanofi S.A.. (5/27/20). "Press Release: Sanofi Announces Pricing of Regeneron Stock Offering". Paris....
- [3] Sanofi S.A.. (5/25/20). "Press Release: Sanofi Intends to Sell Its Equity Investment in Regeneron, Confirms No Change to Ongoing Collaboration". Paris....
- [4] Sanofi S.A.. (5/23/20). "Press Release: Dupixent (dupilumab) Eosinophilic Esophagitis Trial Meets both Co-primary Endpoints". Paris & Tarrytown, NY....
- [5] Calixar SAS. (3/9/20). "Press Release: Calixar Launches New Funding Round to Establish Business Strategy". Lyon....
- [6] Sanofi S.A.. (6/21/19). "Press Release: Sanofi and Regeneron Announce Positive Topline Phase 2 Results for IL-33 Antibody in Asthma". Paris & Tarrytown, NY....
- [7] Sanofi S.A.. (5/7/19). "Press Release: Dupixent (dupilumab) Approved for Severe Asthma by European Commission". Paris & Tarrytown, NY....
- [8] Sanofi S.A.. (2/4/19). "Press Release: CHMP Recommends Approval of Praluent (alirocumab) to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease". Paris & Tarrytown, NY....
- [9] Sanofi S.A.. (1/7/19). "Press Release: Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs". Paris & Tarrytown, NY....
- [10] Sanofi S.A.. (10/16/18). "Press Release: Dupixent (dupilumab) Showed Positive Topline Results in Two Phase 3 trials of Patients with Chronic Rhinosinusitis with Nasal Polyps". Paris & Tarrytown, NY....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top